Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Identifieur interne : 001E25 ( PubMed/Corpus ); précédent : 001E24; suivant : 001E26Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Auteurs : Emmanuel Bachy ; Jane A. Estell ; Eric Van De Neste ; Réda Bouabdallah ; Joan Bargay ; Alain Delmer ; Bénédicte Gelas-Dore ; Maria Gomes Da Silva ; Olivier Fitoussi ; David Belada ; Hervé Maisonneuve ; Tanin Intragumtornchai ; Thierry Lamy ; Peggy Dartigues ; John Francis Seymour ; Gilles SallesSource :
- American journal of hematology [ 1096-8652 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Cohort Studies, Drug Interactions, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects), Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Lymphoma, Follicular (diagnosis), Lymphoma, Follicular (drug therapy), Lymphoma, Follicular (mortality), Male, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Treatment Outcome, Young Adult.
- MESH :
- chemical , adverse effects : Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- diagnosis : Lymphoma, Follicular.
- drug therapy : Lymphoma, Follicular.
- mortality : Lymphoma, Follicular.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- Adult, Aged, Aged, 80 and over, Cohort Studies, Drug Interactions, Female, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Treatment Outcome, Young Adult.
Abstract
An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.
DOI: 10.1002/ajh.24305
PubMed: 26799234
Links to Exploration step
pubmed:26799234Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.</title><author><name sortKey="Bachy, Emmanuel" sort="Bachy, Emmanuel" uniqKey="Bachy E" first="Emmanuel" last="Bachy">Emmanuel Bachy</name><affiliation><nlm:affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</nlm:affiliation></affiliation></author><author><name sortKey="Estell, Jane A" sort="Estell, Jane A" uniqKey="Estell J" first="Jane A" last="Estell">Jane A. Estell</name><affiliation><nlm:affiliation>Hematology Department, Concord Hospital, Concord, NSW, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Van De Neste, Eric" sort="Van De Neste, Eric" uniqKey="Van De Neste E" first="Eric" last="Van De Neste">Eric Van De Neste</name><affiliation><nlm:affiliation>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Bouabdallah, Reda" sort="Bouabdallah, Reda" uniqKey="Bouabdallah R" first="Réda" last="Bouabdallah">Réda Bouabdallah</name><affiliation><nlm:affiliation>Hematology Department, Institut Paoli Calmettes, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bargay, Joan" sort="Bargay, Joan" uniqKey="Bargay J" first="Joan" last="Bargay">Joan Bargay</name><affiliation><nlm:affiliation>Hematology Department, Hospital Son Llàtzer, Palma De Mallorca, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name><affiliation><nlm:affiliation>Hematology Department, CHU De Reims, Reims, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gelas Dore, Benedicte" sort="Gelas Dore, Benedicte" uniqKey="Gelas Dore B" first="Bénédicte" last="Gelas-Dore">Bénédicte Gelas-Dore</name><affiliation><nlm:affiliation>Deparment of Biostatistics, Lysarc, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gomes Da Silva, Maria" sort="Gomes Da Silva, Maria" uniqKey="Gomes Da Silva M" first="Maria" last="Gomes Da Silva">Maria Gomes Da Silva</name><affiliation><nlm:affiliation>Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal.</nlm:affiliation></affiliation></author><author><name sortKey="Fitoussi, Olivier" sort="Fitoussi, Olivier" uniqKey="Fitoussi O" first="Olivier" last="Fitoussi">Olivier Fitoussi</name><affiliation><nlm:affiliation>Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Belada, David" sort="Belada, David" uniqKey="Belada D" first="David" last="Belada">David Belada</name><affiliation><nlm:affiliation>Hematology Department, University Hospital Hradec Kràlové, Prague, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Maisonneuve, Herve" sort="Maisonneuve, Herve" uniqKey="Maisonneuve H" first="Hervé" last="Maisonneuve">Hervé Maisonneuve</name><affiliation><nlm:affiliation>Hematology Department, Centre Hospitalier De La Roche Sur Yon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Intragumtornchai, Tanin" sort="Intragumtornchai, Tanin" uniqKey="Intragumtornchai T" first="Tanin" last="Intragumtornchai">Tanin Intragumtornchai</name><affiliation><nlm:affiliation>Hematology Department, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Lamy, Thierry" sort="Lamy, Thierry" uniqKey="Lamy T" first="Thierry" last="Lamy">Thierry Lamy</name><affiliation><nlm:affiliation>Hematology Department, Centre Hospitalier Pontchaillou, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dartigues, Peggy" sort="Dartigues, Peggy" uniqKey="Dartigues P" first="Peggy" last="Dartigues">Peggy Dartigues</name><affiliation><nlm:affiliation>Hematology Department, Institut Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name><affiliation><nlm:affiliation>Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name><affiliation><nlm:affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26799234</idno><idno type="pmid">26799234</idno><idno type="doi">10.1002/ajh.24305</idno><idno type="wicri:Area/PubMed/Corpus">001E25</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.</title><author><name sortKey="Bachy, Emmanuel" sort="Bachy, Emmanuel" uniqKey="Bachy E" first="Emmanuel" last="Bachy">Emmanuel Bachy</name><affiliation><nlm:affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</nlm:affiliation></affiliation></author><author><name sortKey="Estell, Jane A" sort="Estell, Jane A" uniqKey="Estell J" first="Jane A" last="Estell">Jane A. Estell</name><affiliation><nlm:affiliation>Hematology Department, Concord Hospital, Concord, NSW, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Van De Neste, Eric" sort="Van De Neste, Eric" uniqKey="Van De Neste E" first="Eric" last="Van De Neste">Eric Van De Neste</name><affiliation><nlm:affiliation>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Bouabdallah, Reda" sort="Bouabdallah, Reda" uniqKey="Bouabdallah R" first="Réda" last="Bouabdallah">Réda Bouabdallah</name><affiliation><nlm:affiliation>Hematology Department, Institut Paoli Calmettes, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bargay, Joan" sort="Bargay, Joan" uniqKey="Bargay J" first="Joan" last="Bargay">Joan Bargay</name><affiliation><nlm:affiliation>Hematology Department, Hospital Son Llàtzer, Palma De Mallorca, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name><affiliation><nlm:affiliation>Hematology Department, CHU De Reims, Reims, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gelas Dore, Benedicte" sort="Gelas Dore, Benedicte" uniqKey="Gelas Dore B" first="Bénédicte" last="Gelas-Dore">Bénédicte Gelas-Dore</name><affiliation><nlm:affiliation>Deparment of Biostatistics, Lysarc, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gomes Da Silva, Maria" sort="Gomes Da Silva, Maria" uniqKey="Gomes Da Silva M" first="Maria" last="Gomes Da Silva">Maria Gomes Da Silva</name><affiliation><nlm:affiliation>Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal.</nlm:affiliation></affiliation></author><author><name sortKey="Fitoussi, Olivier" sort="Fitoussi, Olivier" uniqKey="Fitoussi O" first="Olivier" last="Fitoussi">Olivier Fitoussi</name><affiliation><nlm:affiliation>Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Belada, David" sort="Belada, David" uniqKey="Belada D" first="David" last="Belada">David Belada</name><affiliation><nlm:affiliation>Hematology Department, University Hospital Hradec Kràlové, Prague, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Maisonneuve, Herve" sort="Maisonneuve, Herve" uniqKey="Maisonneuve H" first="Hervé" last="Maisonneuve">Hervé Maisonneuve</name><affiliation><nlm:affiliation>Hematology Department, Centre Hospitalier De La Roche Sur Yon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Intragumtornchai, Tanin" sort="Intragumtornchai, Tanin" uniqKey="Intragumtornchai T" first="Tanin" last="Intragumtornchai">Tanin Intragumtornchai</name><affiliation><nlm:affiliation>Hematology Department, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Lamy, Thierry" sort="Lamy, Thierry" uniqKey="Lamy T" first="Thierry" last="Lamy">Thierry Lamy</name><affiliation><nlm:affiliation>Hematology Department, Centre Hospitalier Pontchaillou, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dartigues, Peggy" sort="Dartigues, Peggy" uniqKey="Dartigues P" first="Peggy" last="Dartigues">Peggy Dartigues</name><affiliation><nlm:affiliation>Hematology Department, Institut Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name><affiliation><nlm:affiliation>Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name><affiliation><nlm:affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">American journal of hematology</title><idno type="eISSN">1096-8652</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Cohort Studies</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects)</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Lymphoma, Follicular (diagnosis)</term><term>Lymphoma, Follicular (drug therapy)</term><term>Lymphoma, Follicular (mortality)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Neoplasm Metastasis</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lymphoma, Follicular</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphoma, Follicular</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Lymphoma, Follicular</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Neoplasm Metastasis</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26799234</PMID><DateCreated><Year>2016</Year><Month>03</Month><Day>22</Day></DateCreated><DateCompleted><Year>2016</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Jun</Month></PubDate></JournalIssue><Title>American journal of hematology</Title><ISOAbbreviation>Am. J. Hematol.</ISOAbbreviation></Journal><ArticleTitle>Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.</ArticleTitle><Pagination><MedlinePgn>410-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.24305</ELocationID><Abstract><AbstractText>An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.</AbstractText><CopyrightInformation>© 2016 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bachy</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estell</LastName><ForeName>Jane A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Hematology Department, Concord Hospital, Concord, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van de Neste</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouabdallah</LastName><ForeName>Réda</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hematology Department, Institut Paoli Calmettes, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bargay</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hematology Department, Hospital Son Llàtzer, Palma De Mallorca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmer</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hematology Department, CHU De Reims, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelas-Dore</LastName><ForeName>Bénédicte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Deparment of Biostatistics, Lysarc, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes da Silva</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitoussi</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belada</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hematology Department, University Hospital Hradec Kràlové, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maisonneuve</LastName><ForeName>Hervé</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hematology Department, Centre Hospitalier De La Roche Sur Yon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Intragumtornchai</LastName><ForeName>Tanin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hematology Department, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamy</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hematology Department, Centre Hospitalier Pontchaillou, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Peggy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hematology Department, Institut Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seymour</LastName><ForeName>John Francis</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salles</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hematol</MedlineTA><NlmUniqueID>7610369</NlmUniqueID><ISSNLinking>0361-8609</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008224" MajorTopicYN="N">Lymphoma, Follicular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26799234</ArticleId><ArticleId IdType="doi">10.1002/ajh.24305</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26799234
|texte= Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26799234" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |